Explore News By Topic

06/06/2017

Abiraterone and Enzalutamide equivalent as first-line therapy in metastatic hormone therapy- resistant prostate cancer

A clinical trial reported on at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting found that men who develop metastatic hormone therapy-resistant prostate cancer (mHRPC) have similar outcomes if prescribed either abiraterone or enzalutamide.  Abiraterone and enzalutamide are two hormonal therapies that can be used as first line... Read More

06/06/2017

Your Best Weapon Against Metastatic Prostate Cancer May Be a Genetic Counselor

Mark Meerschaert is alive today because of a genetic counselor, a medical oncologist in Seattle named Heather Cheng, M.D., Ph.D.  (You can read more about Mark’s story here.)  Less than a year ago, Mark was desperate:  hormonal therapy had failed, and traditional chemotherapy was not going to save his life. ... Read More

05/26/2017

FDA approves first precision medicine for the treatment of cancers with certain genetic defects, including prostate cancer

On May 23, 2017, the field of precision medicine achieved a major milestone with the FDA’s first ever approval of a cancer therapy based entirely on a tumor’s unique characteristics and not where the tumor developed in the body.  In other words, while therapies to date have been approved for... Read More

05/22/2017

Prostate cancer cells that commit identify fraud

A new study reported at the 2017 American Association for Cancer Research (AACR) Annual Meeting identified new mechanisms and treatment approach for an aggressive subtype of AR-therapy resistant prostate cancer. Prostate cancers are fueled by male hormones called androgens.  These growth signals are transmitted to cancer cells through the androgen... Read More

05/02/2017

Why has checkpoint immunotherapy been ineffective in treating prostate cancer?

Checkpoint immunotherapy, the relatively new type of cancer treatment making headlines for being able to seemingly cure some patients with melanoma and other cancers, has been notoriously ineffective in prostate cancer.  At the 2017 American Association for Cancer Research (AACR) Annual Meeting, Dr. Padmanee Sharma presented the discovery of at... Read More